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mAbstract
Background: The aim of the present study was to test the potential protective
effects of the organic vanadium salt bis (maltolato) oxovanadium (BMOV; 15 mg/kg)
in the context of renal ischemia/reperfusion (30 min of ischemia) and its effects
on renal oxygenation and renal function in the acute phase of reperfusion
(up to 90 min post-ischemia).
Methods: Ischemia was established in anesthetized and mechanically ventilated male
Wistar rats by renal artery clamping. Renal microvascular and venous oxygenation were
measured using phosphorimetry. Creatinine clearance rate, sodium reabsorption, and
renal oxygen handling efficiency were considered markers for renal function.
Results: The main findings were that BMOV did not affect the systemic and renal
hemodynamic and oxygenation variables and partially protected renal sodium
reabsorption.
Conclusions: Pretreatment with the organic vanadium compound BMOV did not
protect the kidney from I/R injury.
Keywords: Acute kidney injury; Ischemia/reperfusion injury; Vanadium; MicrocirculationBackground
Acute kidney injury (AKI) is a frequent and costly clinical complication in critically ill
patients. Using the RIFLE criteria in 20,126 hospitalized patients, Uchino et al. has
found that 20% of the patients had some degrees of acute renal impairment and 3.7%
of these patients had AKI [1]. Ischemia/reperfusion (I/R) injury occurring during surgery
and shock is one of the major causes of this condition in native and transplanted kidneys
[1-5]. The pathogenesis and pathophysiology of I/R-induced AKI is highly complex [4,5].
In addition to hypoxic hit consequent to ischemia, the reperfusion phase has been associ-
ated with additional renal injury. I/R-induced activation of inflammatory pathways has
been shown to worsen AKI [6-9]. Furthermore, increased production of radical oxygen
species (ROS) and reactive nitrogen species (RNS) [10-13] and a regional imbalance
between vasoactive mediators are believed to be of great importance in the development
of AKI by leading impaired microcirculatory perfusion and to cellular damage, apoptosis,
and irreversible organ failure [4,5].
In this respect, vanadium compounds are promising in the prevention and treatment
of ischemic AKI. Vanadium is an essential trace element in humans and plays various2014 Almac et al.; licensee Springer. This is an Open Access article distributed under the terms of the Creative Commons
ttribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any
edium, provided the original work is properly cited.
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vanadium may play a pivotal role in the regulation of physiological cell growth, survival,
and metabolism. Most biologically active forms of vanadium are the inorganic vanadate
salt vanadyl sulfate (VOSO4) and the organic vanadium salt bis oxovanadium (BMOV).
Especially, the organic BMOV can be used in vitro and in vivo for its beneficial regula-
tory metabolic roles without major side effects. BMOV and other vanadium com-
pounds have demonstrated protective against ischemic cascades, apoptosis, and
vascular endothelial dysfunction while supporting tissue repair in the heart and the
brain [14-16].
In the present study, we therefore aimed to investigate the potential protective effects
of BMOV in the acute phase of renal I/R and AKI. To this end, rats received 0 or
15 mg/kg BMOV intravenously 30 min before renal artery clamping, and we measured
renal oxygenation and renal function up to 90 min of reperfusion.
Methods
Animals
All experiments in this study were approved by the Institutional Animal Experimenta-
tion Committee of the Academic Medical Center of the University of Amsterdam. Care
and handling of the animals were in accordance with the EU Directive 2010/63/EU for
animal experiments and guidelines for Institutional and Animal Care and Use Commit-
tees. The study has been carried out in accordance with the National Institutes of
Health (NIH) Guide for the Care and Use of Laboratory Animals. Experiments were
performed on 18 Wistar male rats (Harlan, the Netherlands) with mean ± SD body
weight of 320 ± 30 g.
Surgical preparation
The rats were anesthetized with an intraperitoneal injection of a mixture of
100 mg/kg ketamine (Nimatek®, Eurovet, Bladel, the Netherlands), 0.5 mg/kg medetomi-
dine (Domitor, Pfizer, New York, NY, USA), and 0.05 mg/kg atropine sulfate (Centrafarm,
Etten-Leur, the Netherlands). After tracheotomy, the animals were mechanically venti-
lated with a FiO2 of 0.4. Body temperature was maintained at 37°C ± 0.5°C during the
entire experiment by external warming. The ventilator settings were adjusted to maintain
end-tidal PCO2 between 30 and 35 mmHg and arterial PCO2 between 35 and 40 mmHg.
Vessels were cannulated with polyethylene catheters (outer diameter = 0.9 mm;
Braun, Melsungen, Germany) for drug and fluid administration and hemodynamic
monitoring. A catheter in the right carotid artery was connected to a pressure trans-
ducer to monitor mean arterial blood pressure (MAP) and heart rate. The right femoral
artery was cannulated for blood sampling. The right femoral vein was cannulated for
continuous infusion of Ringer’s lactate (15 mL/kg/h; Baxter, Utrecht, the Netherlands)
and ketamine (50 mg/kg/h; Nimatek®, Eurovet, Bladel, the Netherlands).
The left kidney was exposed, decapsulated, and immobilized in a Lucite kidney cup
(K. Effenberger, Pfaffingen, Germany) via a 4-cm incision in the left flank. Renal vessels
were carefully separated under preservation of nerves and adrenal gland. A perivascular
ultrasonic transit time flow probe was placed around the left renal artery (type 0.7 RB;
Transonic Systems Inc., Ithaca, NY, USA) and connected to a flow meter (T206, Transonic
Systems Inc.) to continuously measure renal blood flow (RBF). An estimation of the renal
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was isolated, ligated, and cannulated with a polyethylene catheter for urine collection.
After the surgical protocol (approximately 60 min), one optical fiber was placed
1 mm above the decapsulated kidney and another optical fiber 1 mm above the renal
vein to measure oxygenation in the renal microvasculature and renal vein, respectively,
using phosphorimetry. A small piece of aluminum foil was placed on the dorsal site of
the renal vein to prevent the contribution of underlying tissue to the phosphorescence
signal in the venous oxygenation measurement. Oxyphor G2 (a two-layer glutamate
dendrimer of tetra-(4-carboxy-phenyl) benzoporphyrin, Oxygen Enterprises Ltd.,
Philadelphia, PA, USA) was subsequently infused (6 mg/kg IV over 5 min) followed
by a 30-min stabilization period. A short description of phosphorimetry is given
below, and a more detailed description of the technology has been provided else-
where [17-20].
Experimental protocol
After baseline measurements were performed 30 min after Oxyphor G2 infusion, the
rats were randomly assigned to one of the following groups: sham-operated time
control (n = 6), I/R control (n = 6), and I/R with 15 mg/kg BMOV (n = 6). Considering
this is the first study in which BMOV is being utilized in a model of renal I/R injury,
we decided to use the recommended dosage (15 mg/kg) by CFM Pharma (Almere, the
Netherlands). BMOV solutions were prepared in 2-mL isotonic saline, and infusion was
initiated 30 min prior to renal ischemia at an infusion rate of 2 mL/h. Control rats
received the same volume of isotonic saline without BMOV. Renal ischemia was
created by 30-min clamping of the renal artery, and following the release of the clamp,
measurements were continued up to 90 min of reperfusion. The experiments were
terminated by infusion of 1 mL of 3 M potassium chloride (KCl).
Blood variables
Arterial blood samples (0.5 mL) were taken from the femoral artery at baseline and 15
and 90 min after reperfusion. The blood samples were replaced by the same volume of
Voluven® (Fresenius Kabi Ltd., Runcom, UK). Samples were analyzed for blood gas
values (ABL505 blood gas analyzer, Radiometer, Copenhagen, Denmark), hemoglobin
concentration, and hemoglobin oxygen saturation (OSM3, Radiometer). Additionally,
plasma creatinine concentrations were determined in all samples.
Renal microvascular and venous oxygenation
Microvascular oxygen tension in the renal cortex (CμPO2), outer medulla (MμPO2),
and renal venous oxygen tension (PrvO2) were measured by oxygen-dependent quench-
ing of phosphorescence lifetimes of the systemically infused albumin-targeted (and
therefore circulation-confined) phosphorescent dye Oxyphor G2. Oxyphor G2
(a two-layer glutamate dendrimer of tetra-(4-carboxy-phenyl) benzoporphyrin) has
two excitation peaks (λexcitation1 = 440 nm, λexcitation2 = 632 nm) and one emission peak
(λemission = 800 nm). These optical properties allow (near) simultaneous lifetime measure-
ments in microcirculation of the kidney cortex and the outer medulla due to different
optical penetration depths of the excitation light. For the measurement of renal venous
PO2 (PrvO2), a mono-wavelength phosphorimeter was used. Oxygen measurements based
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be quenched by energy transfer to oxygen resulting in the shortening of the phospho-
rescence lifetime. A linear relationship between reciprocal phosphorescence lifetime
and oxygen tension (given by the Stern-Volmer relation) allows quantitative measurement
of PO2 [17-20].
Renal oxygen delivery and consumption
Arterial oxygen content (AOC) was calculated by (1.31 × hemoglobin × SaO2) + (0.003 ×
PaO2), where SaO2 is arterial oxygen saturation and PaO2 is arterial partial pressure of oxy-
gen. Renal venous oxygen content (RVOC) was calculated as (1.31 × hemoglobin × SrvO2) +
(0.003 × PrvO2), where SrvO2 is venous oxygen saturation and PrvO2 is renal vein partial
pressure of oxygen (measured using phosphorimetry). Renal oxygen delivery per gram of
renal tissue was calculated as DO2 (mL/min/g) = RBF ×AOC. Renal oxygen consumption
per gram of renal tissue was calculated as VO2 (mL/min/g) = RBF × (AOC −RVOC). The
renal oxygen extraction ratio was calculated as O2 ER (%) = VO2/DO2 × 100.
Renal function
For the analysis of urine volume, creatinine concentration, and sodium (Na+) concentration
at the end of the protocol, urine samples from the left ureter were collected for 10 min.
Creatinine clearance rate (CLcrea) per gram of renal tissue was calculated with the standard
formula: CLcrea (mL/min/g) = (U ×V)/P, where U is the urine creatinine concentration,V is
the urine volume per unit time, and P is the plasma creatinine concentration. Renal oxygen
consumption efficiency for sodium transport (VO2/TNa+) was assessed as the ratio of the
renal VO2 over the total amount of sodium reabsorbed (TNa+, [mmol/min]). TNa+ was
calculated according to the following: ((CLcrea × PNa+) − (UNa+ ×V)), where PNa+ is the
plasma concentration of sodium.
Data analysis
Statistical analysis was performed using GraphPad Prism version 5.0 for Windows
(GraphPad Software, San Diego, CA, USA). Data are presented as mean ± SD unless
otherwise stated. Statistical significance of differences between groups was tested
using one-way ANOVA with Bonferroni post hoc tests. P values <0.05 were considered
significant.
Results
Table 1 shows the systemic and renal hemodynamic variables: MAP, RBF, RVR, DO2,
VO2, CμpO2, and MμpO2 at baseline (BL), 15 min after reperfusion (R15), and 90 min
after reperfusion (R90). Figure 1 shows the renal DO2 and VO2 and TNa+, renal oxygen
handling efficacy (VO2/TNa+), and creatinine clearance rate at the end of the protocol.
At baseline, there were no significant differences between groups in any of these
variables.
Systemic and renal hemodynamic and oxygenation variables
Renal I/R did not significantly affect MAP, but decreased RBF and increased RVR, which
was associated with decreases in both renal DO2 and VO2. BMOV did not affect any of
these macrocirculatory hemodynamic and oxygenation variables. CμpO2 and MμpO2
Table 1 Systemic and renal hemodynamic variables at BL, R15, and R90
BL (t = 0 min) R15 (t = 45 min) R90 (t = 120 min)
MAP [mmHg]
Time control 104 ± 4 101 ± 4 99 ± 4
I/R 108 ± 11 104 ± 7 90 ± 18
I/R + BMOV 108 ± 13 102 ± 24 92 ± 12
RBF [mL/min]
Time control 4.7 ± 0.5 4.6 ± 0.6 4.6 ± 0.5
I/R 4.6 ± 1.0 2.8 ± 0.5* 3.3 ± 0.1*
I/R + BMOV 4.2 ± 1.1 2.7 ± 0.4* 3.4 ± 0.3*
RVR [dyn/s/cm5]
Time control 1,777 ± 172 1,793 ± 244 1,735 ± 153
I/R 2,004 ± 672 3,097 ± 451* 2,216 ± 502*
I/R + BMOV 2,190 ± 723 3,217 ± 1,251* 2,178 ± 240*
DO2 [mL O2/min/g]
Time control 1.21 ± 0.14 1.13 ± 0.14 1.18 ± 0.11
I/R 1.10 ± 0.24 0.65 ± 0.13* 0.72 ± 0.03*
I/R + BMOV 1.05 ± 0.32 0.64 ± 0.14* 0.77 ± 0.10*
VO2 [mL O2/min/g]
Time control 0.14 ± 0.07 0.13 ± 0.04 0.15 ± 0.02
I/R 0.13 ± 0.10 0.10 ± 0.02* 0.09 ± 0.01*
I/R + BMOV 0.13 ± 0.07 0.11 ± 0.05 0.10 ± 0.04*
CμpO2 [mmHg]
Time control 65 ± 7 62 ± 7 60 ± 6
I/R 63 ± 6 59 ± 9 54 ± 5
I/R + BMOV 66 ± 2 61 ± 9 64 ± 6**
MμpO2 [mmHg]
Time control 52 ± 6 51 ± 9 49 ± 7
I/R 54 ± 5 50 ± 5 49 ± 2
I/R + BMOV 50 ± 5 50 ± 4 48 ± 3
*p < 0.05 vs time control; **p < 0.05 vs I/R.
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significantly higher in the BMOV treated group compared to the I/R control group.
Renal function parameters
At the end of the protocol, renal DO2 and VO2 were decreased proportionally. Renal
TNa+ was significantly reduced in the I/R control group, but in the group receiving
BMOV, this decrease was not statistically significant. Renal creatinine clearance rate
decreased after I/R, both with and without BMOV administration; however, it did not
reach a level of significance in both groups. Similarly renal oxygen handling efficacy
(VO2/TNa+) were maintained after I/R in both groups.
Discussion
The aim of the present study was to test the potential protective effects of BMOV
(15 mg/kg) in the acute phase of renal I/R and its effects on renal oxygenation and
renal function up to 90 min post-ischemia. The main findings were that (1) BMOV did
Figure 1 DO2 and VO2 (A), TNa+ (B), VO2/TNa+ (C), and CLcrea (D) at the end of the protocol.
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variables and (2) BMOV partially protected TNa+ after I/R. Furthermore, we found that
microcirculatory oxygenation in the renal cortex and medulla tended to decrease after
I/R. In contrast to the non-treated animals, cortical microcirculatory oxygenation was
preserved in the BMOV-treated animals, but no significant differences were seen in the
renal medulla.
To our knowledge, this is the first study investigating the effects of organic vanadium
compound BMOV in the context of renal I/R injury. Inorganic vanadium compounds
are documented to be nephrotoxic, particularly if used chronically [21], but organic
vanadium compounds, such as BMOV, are known to have less side effects. In experi-
mental studies, both pre- and post-ischemic administrations of vanadium compounds
have been shown to be cytoprotective. We believe that preventive strategies are
essential in order to minimize I/R injury. Therefore, we administered BMOV 30 min
before the onset of ischemia. The optimal dosage of BMOV in order to prevent renal I/R
injury is unknown, but administration of 15 mg/kg is recommended by the manufacturer,
which is also comparable to the doses used in earlier studies [22].
Earlier studies investigating the beneficial effects of vanadium compounds after I/R
injury in vivo have mainly been focused on the brain and on the heart. However, the
type of vanadium, the type of administration, and the timing of administration varied
significantly between studies. In the context of brain I/R, Kawano et al. showed in adult
Mongolian gerbils that were subjected to 5-min forebrain ischemia that intraventricular
injection of orthovanadate 30 min before ischemia blocked delayed neuronal death
[23]. Hasegawa et al. demonstrated the neuroprotective effects of post-ischemic
intraperitoneal administration of sodium orthovanadate in rats with transient middle
cerebral artery occlusion 1 and 28 days after ischemia [24]. In a subsequent study, the
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cerebral artery occlusion) and the neuroprotective dose (2 mL/kg and 12.5, 25, 37.5,
and 50 mM) of sodium orthovanadate in rats [24]. Later, Shioda et al. found in a mouse
model of transient middle cerebral artery occlusion that pre- and post-treatments with
bis(1-oxy-2-pyridinethiolato)oxovanadium(IV) significantly reduced infarct volume in a
dose-dependent manner and thereby provided neuroprotection in brain I/R injury [25].
The same group also showed that i.p. administration of bis(1-oxy-2-pyridinethiolato)
oxovanadium(IV) markedly enhanced brain ischemia-induced neurogenesis in the
subgranular zone of the mouse hippocampus [26]. Additionally, they found that
amelioration of cognitive dysfunction following brain ischemia was positively correlated
with vanadium-induced neurogenesis. Li et al. found that bisperoxovanadium attenuated
cellular apoptosis in developing rat brain rescued neurons from hypoxia-ischemia brain
damage [27]. Liu et al., furthermore, showed that 4 weeks of administration of sodium
orthovanadate in drinking water significantly improved the outcome in rats with
streptozotocin-induced diabetes after cerebral ischemia and reperfusion in terms of
neurobehavioral function [28]. In the context of myocardial I/R, Geraldes et al. showed in
isolated perfused rat hearts that the presence of vanadate during ischemia resulted in
attenuation of acidosis and reduced lactate accumulation [29]. In anesthetized rats, Liem
et al. showed that intravenous infusion of BMOV in doses of 3.3, 7.5, and 15 mg/kg i.v.
decreased myocardial infarct size dose-dependently when administered before occlusion
[22]. Administration of the low dose during ischemia just before reperfusion was ineffect-
ive, but administration of the higher doses was equally cardioprotective as compared with
administration before occlusion. Bhuiyan et al. showed that post-ischemic treatment with
bis(1-oxy-2-pyridinethiolato)oxovanadium(IV) significantly reduced infarct size and
improved cardiac function in a dose-dependent manner [16]. That same group also
showed that post-treatment with vanadyl sulfate significantly reduced the infarct size and
significantly decreased the elevated left ventricular end-diastolic pressure, improved left
ventricular developed pressure, and left ventricular contractility in a dose-dependent
manner. Keyes et al. showed that the intravenous administration of bisperoxovanadium
significantly reduced myocardial infarct size and improved cardiac function [30].
As demonstrated by many of the studies referenced above, vanadium compounds
activate protein kinase B (Akt) signaling through inhibition of protein tyrosine
phosphatases. Akt is an important signaling molecule that modulates many cellular
processes such as cell growth, survival, and metabolism. Hence, by activating Akt
signaling, vanadium compounds elicit cytoprotection in brain and myocardial I/R
injuries. This would make vanadium also a potential candidate for reducing I/R injury
in the kidney.
It must be acknowledged that our study has some limitations. Investigation of the
dose-dependent response to BMOV, a longer follow-up after I/R, the acting
mechanisms of BMOV, and histological evaluation of the effects of I/R and BMOV are
the important limitations of our study. Since the potential benefits of BMOV in the
context of I/R were never studied before, we chose to perform a relatively simple,
short-term study in which we mainly focused on the effects of BMOV on renal oxygen-
ation and function. However, longer studies are required in which different doses of
BMOV are given and more detailed analysis of the involved pathways is done, together
with histological evaluation. Furthermore, we used creatinine clearance rate and
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can lead to imprecision due to back leak phenomena and slight tubular creatinine
secretion.
Conclusions
In conclusion, pretreatment with the organic vanadium compound BMOV did not sig-
nificantly affect the systemic or the renal hemodynamic and oxygenation variables and
only partially protected renal sodium reabsorption after I/R. However, longer studies
are required in which different doses of BMOV are given and more detailed analysis of
the involved pathways is done, together with histological evaluation to fully understand
the potential protective role of BMOV in the context of renal I/R.
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